(Image: Shutterstock)
A longtime tracker on pharma R&D productivity takes a post-pandemic plunge back to a bleak reality
So much for the “turnaround.”
The biopharma industry tossed the old playbook on R&D, broke every rule and bent every trend during the pandemic. Some of the players were rewarded with massive windfalls. And now that Covid-19 isn’t forcing radical change, some of the old trends are back.
With a vengeance.
Even the relentless drop in the internal rate of return (IRR) analysts at Deloitte had tracked at major pharma companies’ R&D groups for years before the pandemic sparked a remarkable rally has reared back up again.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.
